美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Kyverna Therapeutics

7.68

-0.4200-5.19%

盤後：7.680.00000.00%19:23 EST

成交量：41.27萬

成交額：323.46萬

市值：4.39億

市盈率：-2.06

高：8.08

開：8.00

低：7.67

收：8.10

52周最高：13.67

52周最低：1.78

股本：5,712.95萬

流通股本：3,329.70萬

量比：0.81

換手率：1.24%

股息：- -

股息率：- -

每股收益(TTM):-3.7205

每股收益(LYR):-3.3254

淨資產收益率：-70.82%

總資產收益率：-40.75%

市淨率：2.89

市盈率(LYR):-2.31

資料載入中...

總覽公司新聞資訊公告

Kyverna Therapeutics, Inc.盤中異動股價大跌5.06%

Kyverna Therapeutics, Inc.盤中異動下午盤快速跳水5.06%報8.26美元

BUZZ--美國股票走勢-Robinhood Markets、大麻股票、凱悦酒店

BUZZ-Kyverna Therapeutics 因 1 億美元股票交易大幅折價而暴跌

BUZZ-Kyverna Therapeutics 因 1 億美元股票銷售計劃而下跌

新聞稿：Kyverna Therapeutics宣佈擬進行普通股的公開發行

BUZZ--美國股票走勢-通用美元公司、火箭實驗室、應用材料公司

BUZZ--美國股票走勢-通用美元公司、火箭實驗室、應用材料公司

BUZZ-細胞療法達到中期研究的主要目標後，Kyverna業績大增

Kyverna的細胞療法達到了中期研究的主要目標

Kyverna Therapeutics公布Miv-Cel (Kyv-101)在僵人綜合徵註冊Kysa-8試驗中的積極關鍵數據

Kyverna Therapeutics將發布Kyv-101在僵人綜合症註冊性第二階段Kysa-8試驗的頂線結果

Caribou Biosciences報告了關於同種異體CAR T療法的臨牀數據，而Kyverna Therapeutics則推進了自身免疫項目Caribou Biosciences Reports Clinical Data on Allogeneic CAR T Therapies While Kyverna Therapeutics Advances Autoimmune Program

Kyverna Therapeutics公司預計現金流可持續至2027年，支持其SPS的BLA申請及Mg三期臨牀試驗

Kyverna Therapeutics公布Kysa-6研究中Kyv-101在廣泛性重症肌無力治療中的積極一期2臨牀數據

Kyverna Therapeutics在2025年Acr Convergence會議上展示的1期研究數據強調了Kyv-101在類風濕性關節炎中的潛力

Kyverna Therapeutics, Inc.盤中異動股價大跌5.02%

Kyverna Therapeutics將在Ectrims會議上展示Kyv-101治療多發性硬化症的1期研究者發起試驗數據，凸顯該藥物潛力

Kyverna Therapeutics在虛擬專家會議上重點介紹神經免疫學CAR-T業務及重症肌無力註冊性3期試驗設計

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/KYTX/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"KYTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KYTX\",,,,,undefined,":{"symbol":"KYTX","market":"US","secType":"STK","nameCN":"Kyverna Therapeutics","latestPrice":7.68,"timestamp":1771621200000,"preClose":8.1,"halted":0,"volume":412714,"hourTrading":{"tag":"盘后","latestPrice":7.68,"preClose":7.68,"latestTime":"19:23 EST","volume":10389,"amount":79785.02,"timestamp":1771633431349,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.05185185185185184,"floatShares":33297000,"shares":57129503,"eps":-3.72055,"marketStatus":"休市中","change":-0.42,"latestTime":"02-20 16:00:00 EST","open":8,"high":8.08,"low":7.67,"amount":3234572.099194,"amplitude":0.050617,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.72055,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1771837200000},"marketStatusCode":7,"adr":0,"listingDate":1707368400000,"exchange":"NASDAQ","adjPreClose":8.1,"preHourTrading":{"tag":"盘前","latestPrice":8.05,"preClose":8.1,"latestTime":"09:24 EST","volume":920,"amount":7342.590104000001,"timestamp":1771597461170,"change":-0.05,"changeRate":-0.006173,"amplitude":0.020988},"postHourTrading":{"tag":"盘后","latestPrice":7.68,"preClose":7.68,"latestTime":"19:23 EST","volume":10389,"amount":79785.02,"timestamp":1771633431349,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.8071301734333017,"impliedVol":1.0528,"impliedVolPercentile":0.2231},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KYTX\",,,,,undefined,":{"symbol":"KYTX","floatShares":33297000,"roa":"-40.75%","roe":"-70.82%","lyrEps":-3.325379,"volumeRatio":0.8071301734333017,"shares":57129503,"dividePrice":0,"high":8.08,"amplitude":0.050617,"preClose":8.1,"low":7.67,"week52Low":1.78,"pbRate":"2.89","psRate":"1555.87","week52High":13.67,"institutionHeld":0,"latestPrice":7.68,"eps":-3.72055,"divideRate":0,"volume":412714,"delay":0,"ttmEps":-3.72055,"open":8,"prevYearClose":9.4,"prevWeekClose":7.26,"prevMonthClose":8.01,"prevQuarterClose":9.4,"fiveDayClose":7.36,"twentyDayClose":10.51,"sixtyDayClose":7.09},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KYTX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-12","symbol":"KYTX","fiscalQuarterEnding":"2025/09","expectedEps":-0.97,"name":null,"time":"盤後","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"post","actualEps":-0.85},{"market":"US","date":"2025-08-12","symbol":"KYTX","fiscalQuarterEnding":"2025/06","expectedEps":1,"name":null,"time":"盤後","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"post","actualEps":-0.97},{"market":"US","date":"2025-05-13","symbol":"KYTX","fiscalQuarterEnding":"2025/03","expectedEps":-1.21,"name":null,"time":"盤後","type":"earning","dateTimestamp":1747108800000,"reportTimeType":"post","actualEps":-1.03},{"market":"US","date":"2025-03-27","symbol":"KYTX","fiscalQuarterEnding":"2024/12","expectedEps":-0.87,"name":null,"time":"盤後","type":"earning","dateTimestamp":1743048000000,"reportTimeType":"post","actualEps":-0.88},{"market":"US","date":"2024-11-13","symbol":"KYTX","fiscalQuarterEnding":"2024/09","expectedEps":-0.77,"name":null,"time":"盤後","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"post","actualEps":-0.8}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KYTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KYTX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":6,"updateTime":1755666000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/KYTX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"KYTX","date":"2026-02-20","current":-2.064211,"percent":0.396857,"low":-26.836094,"twenty":-4.986457,"median":-2.025703,"eighty":-1.014247,"high":-0.615209,"avg":-4.596975,"sd":6.321671,"marketCap":462748974},"quantilePoints":[{"date":"2024-02-09","current":-25.410847,"twenty":-24.055602,"median":-22.022734,"eighty":-19.989866,"marketCap":1224675750},{"date":"2024-02-16","current":-26.541682,"twenty":-26.641604,"median":-26.505996,"eighty":-25.427787,"marketCap":1279176368},{"date":"2024-02-23","current":-24.230994,"twenty":-26.541682,"median":-25.495549,"eighty":-24.578936,"marketCap":1167812779},{"date":"2024-03-01","current":-24.239916,"twenty":-26.505996,"median":-25.105309,"eighty":-24.54325,"marketCap":1168242754},{"date":"2024-03-08","current":-25.676289,"twenty":-26.318643,"median":-25.069622,"eighty":-24.578936,"marketCap":1237468769},{"date":"2024-03-15","current":-26.354329,"twenty":-26.354329,"median":-25.311608,"eighty":-24.712759,"marketCap":1270146888},{"date":"2024-03-22","current":-23.999034,"twenty":-26.354329,"median":-25.16776,"eighty":-24.239916,"marketCap":1156633422},{"date":"2024-03-28","current":-17.2201,"twenty":-26.32578,"median":-25.042858,"eighty":-23.820602,"marketCap":1039508532},{"date":"2024-04-05","current":-15.927342,"twenty":-26.311505,"median":-24.815357,"eighty":-20.313915,"marketCap":961469941},{"date":"2024-04-12","current":-17.062969,"twenty":-25.959995,"median":-24.578936,"eighty":-17.608641,"marketCap":1030023179},{"date":"2024-04-19","current":-13.577524,"twenty":-25.715544,"median":-24.235455,"eighty":-16.573007,"marketCap":819620788},{"date":"2024-04-26","current":-11.384836,"twenty":-25.597779,"median":-23.86521,"eighty":-16.071617,"marketCap":687256989},{"date":"2024-05-03","current":-10.734886,"twenty":-25.51207,"median":-23.093494,"eighty":-15.443094,"marketCap":648022117},{"date":"2024-05-10","current":-10.427767,"twenty":-25.427787,"median":-18.634621,"eighty":-13.461819,"marketCap":629482562},{"date":"2024-05-17","current":-8.660987,"twenty":-25.252064,"median":-17.663681,"eighty":-11.317698,"marketCap":657507471},{"date":"2024-05-24","current":-7.059414,"twenty":-25.176682,"median":-17.2201,"eighty":-10.732029,"marketCap":535922482},{"date":"2024-05-31","current":-7.116207,"twenty":-25.108877,"median":-16.627288,"eighty":-10.256351,"marketCap":540234007},{"date":"2024-06-07","current":-7.456968,"twenty":-25.053564,"median":-16.309455,"eighty":-9.030538,"marketCap":566103153},{"date":"2024-06-14","current":-5.412407,"twenty":-25.026799,"median":-16.020192,"eighty":-8.479248,"marketCap":410888275},{"date":"2024-06-21","current":-4.390126,"twenty":-24.958995,"median":-15.870204,"eighty":-7.953341,"marketCap":333280836},{"date":"2024-06-28","current":-4.259502,"twenty":-24.826956,"median":-14.259614,"eighty":-7.613717,"marketCap":323364330},{"date":"2024-07-05","current":-3.978375,"twenty":-24.748445,"median":-13.641804,"eighty":-7.429707,"marketCap":302022284},{"date":"2024-07-12","current":-5.56007,"twenty":-24.685994,"median":-12.649024,"eighty":-7.150283,"marketCap":422098238},{"date":"2024-07-19","current":-5.685015,"twenty":-24.571799,"median":-11.216991,"eighty":-6.028046,"marketCap":431583592},{"date":"2024-07-26","current":-5.588466,"twenty":-24.482583,"median":-10.813451,"eighty":-5.596417,"marketCap":424254000},{"date":"2024-08-02","current":-4.117518,"twenty":-24.238132,"median":-10.584898,"eighty":-5.421494,"marketCap":312585519},{"date":"2024-08-09","current":-3.725644,"twenty":-24.184602,"median":-9.999228,"eighty":-5.056881,"marketCap":282836000},{"date":"2024-08-16","current":-3.830678,"twenty":-23.972269,"median":-9.395703,"eighty":-4.700218,"marketCap":290809782},{"date":"2024-08-23","current":-4.597951,"twenty":-23.820602,"median":-8.80297,"eighty":-4.562778,"marketCap":349058032},{"date":"2024-08-30","current":-4.56385,"twenty":-23.561877,"median":-8.433813,"eighty":-4.558634,"marketCap":346469221},{"date":"2024-09-06","current":-4.171688,"twenty":-23.2407,"median":-8.189602,"eighty":-4.480996,"marketCap":316697893},{"date":"2024-09-13","current":-4.092119,"twenty":-22.946288,"median":-7.78069,"eighty":-4.395806,"marketCap":310657334},{"date":"2024-09-20","current":-3.631756,"twenty":-20.733738,"median":-7.624508,"eighty":-4.308092,"marketCap":275708384},{"date":"2024-09-27","current":-2.97247,"twenty":-18.634621,"median":-7.456968,"eighty":-4.211473,"marketCap":225658035},{"date":"2024-10-04","current":-2.63146,"twenty":-17.741488,"median":-7.394495,"eighty":-4.171688,"marketCap":199769924},{"date":"2024-10-11","current":-2.983837,"twenty":-17.707293,"median":-7.116207,"eighty":-4.052335,"marketCap":226520973},{"date":"2024-10-18","current":-3.205494,"twenty":-17.620069,"median":-6.641982,"eighty":-3.978375,"marketCap":243348245},{"date":"2024-10-25","current":-2.909952,"twenty":-17.56293,"median":-5.951944,"eighty":-3.964176,"marketCap":220911882},{"date":"2024-11-01","current":-2.779231,"twenty":-17.2201,"median":-5.608344,"eighty":-3.873307,"marketCap":210988106},{"date":"2024-11-08","current":-3.006571,"twenty":-17.062969,"median":-5.514635,"eighty":-3.751109,"marketCap":228246847},{"date":"2024-11-15","current":-1.697135,"twenty":-16.627288,"median":-5.392529,"eighty":-3.322005,"marketCap":187796512},{"date":"2024-11-22","current":-1.712741,"twenty":-16.355881,"median":-5.065967,"eighty":-3.177076,"marketCap":189523376},{"date":"2024-11-29","current":-2.251143,"twenty":-16.350167,"median":-4.969419,"eighty":-3.054313,"marketCap":249100201},{"date":"2024-12-06","current":-1.775165,"twenty":-16.285886,"median":-4.789428,"eighty":-3.003161,"marketCap":196430834},{"date":"2024-12-13","current":-1.724446,"twenty":-16.121613,"median":-4.674093,"eighty":-2.977017,"marketCap":190818525},{"date":"2024-12-20","current":-1.560584,"twenty":-16.033048,"median":-4.573541,"eighty":-2.950873,"marketCap":172686448},{"date":"2024-12-27","current":-1.556683,"twenty":-15.964482,"median":-4.562178,"eighty":-2.903132,"marketCap":172254731},{"date":"2025-01-03","current":-1.599599,"twenty":-15.904487,"median":-4.538274,"eighty":-2.797418,"marketCap":177003609},{"date":"2025-01-10","current":-1.346004,"twenty":-15.82735,"median":-4.480996,"eighty":-2.693979,"marketCap":148942061},{"date":"2025-01-17","current":-1.299186,"twenty":-15.443094,"median":-4.435561,"eighty":-2.615547,"marketCap":143761467},{"date":"2025-01-24","current":-1.404526,"twenty":-14.591731,"median":-4.395806,"eighty":-2.532048,"marketCap":155417803},{"date":"2025-01-31","current":-1.264073,"twenty":-13.927497,"median":-4.353211,"eighty":-2.095084,"marketCap":139876022},{"date":"2025-02-07","current":-1.170438,"twenty":-13.706085,"median":-4.259502,"eighty":-1.931223,"marketCap":129514836},{"date":"2025-02-14","current":-1.182143,"twenty":-13.577524,"median":-4.21845,"eighty":-1.814179,"marketCap":130809984},{"date":"2025-02-21","current":-1.084606,"twenty":-13.114702,"median":-4.187318,"eighty":-1.73693,"marketCap":120017081},{"date":"2025-02-28","current":-1.108015,"twenty":-12.719019,"median":-4.171688,"eighty":-1.688552,"marketCap":122607378},{"date":"2025-03-07","current":-1.01438,"twenty":-12.020501,"median":-4.104819,"eighty":-1.598038,"marketCap":112246191},{"date":"2025-03-14","current":-0.975365,"twenty":-11.480543,"median":-3.998252,"eighty":-1.555903,"marketCap":107929030},{"date":"2025-03-21","current":-0.928548,"twenty":-11.116285,"median":-3.978412,"eighty":-1.525471,"marketCap":102748436},{"date":"2025-03-28","current":-0.678003,"twenty":-10.923443,"median":-3.972766,"eighty":-1.481775,"marketCap":86429836},{"date":"2025-04-04","current":-0.671223,"twenty":-10.829164,"median":-3.959945,"eighty":-1.403746,"marketCap":85565537},{"date":"2025-04-11","current":-0.698343,"twenty":-10.750599,"median":-3.915931,"eighty":-1.33508,"marketCap":89022731},{"date":"2025-04-17","current":-0.630601,"twenty":-10.726315,"median":-3.836362,"eighty":-1.299186,"marketCap":80387103},{"date":"2025-04-25","current":-0.711969,"twenty":-10.557757,"median":-3.76816,"eighty":-1.283581,"marketCap":90759633},{"date":"2025-05-02","current":-0.772995,"twenty":-10.436338,"median":-3.711325,"eighty":-1.243785,"marketCap":98539030},{"date":"2025-05-09","current":-0.715359,"twenty":-10.170644,"median":-3.266591,"eighty":-1.184484,"marketCap":91191822},{"date":"2025-05-16","current":-0.68951,"twenty":-9.982087,"median":-3.188443,"eighty":-1.152492,"marketCap":100267785},{"date":"2025-05-23","current":-0.73409,"twenty":-9.837812,"median":-3.142975,"eighty":-1.119719,"marketCap":106750616},{"date":"2025-05-30","current":-0.781642,"twenty":-9.466412,"median":-3.049198,"eighty":-1.09553,"marketCap":113665635},{"date":"2025-06-06","current":-0.873775,"twenty":-9.030538,"median":-3.023622,"eighty":-1.030766,"marketCap":127063486},{"date":"2025-06-13","current":-1.02832,"twenty":-8.929052,"median":-2.986679,"eighty":-1.018767,"marketCap":149537300},{"date":"2025-06-20","current":-0.864859,"twenty":-8.793883,"median":-2.980995,"eighty":-1.008108,"marketCap":125766920},{"date":"2025-06-27","current":-1.031292,"twenty":-8.738225,"median":-2.966787,"eighty":-0.98785,"marketCap":149969489},{"date":"2025-07-03","current":-0.835139,"twenty":-8.660987,"median":-2.95542,"eighty":-0.975365,"marketCap":121445033},{"date":"2025-07-11","current":-1.061012,"twenty":-8.20664,"median":-2.912794,"eighty":-0.974824,"marketCap":154291376},{"date":"2025-07-18","current":-1.209614,"twenty":-8.200961,"median":-2.836066,"eighty":-0.975365,"marketCap":175900813},{"date":"2025-07-25","current":-1.260138,"twenty":-8.178243,"median":-2.779231,"eighty":-0.975365,"marketCap":183248021},{"date":"2025-08-01","current":-1.061012,"twenty":-7.803407,"median":-2.688295,"eighty":-0.975365,"marketCap":154291376},{"date":"2025-08-08","current":-0.98374,"twenty":-7.78069,"median":-2.625776,"eighty":-0.98374,"marketCap":143054469},{"date":"2025-08-15","current":-0.964666,"twenty":-7.68982,"median":-2.585992,"eighty":-0.974824,"marketCap":153089661},{"date":"2025-08-22","current":-0.975567,"twenty":-7.678462,"median":-2.530603,"eighty":-0.962936,"marketCap":154819487},{"date":"2025-08-29","current":-1.008267,"twenty":-7.570554,"median":-2.118493,"eighty":-0.964666,"marketCap":160008967},{"date":"2025-09-05","current":-0.989192,"twenty":-7.52512,"median":-1.993646,"eighty":-0.964666,"marketCap":156981771},{"date":"2025-09-12","current":-1.130894,"twenty":-7.468327,"median":-1.952681,"eighty":-0.972792,"marketCap":179469518},{"date":"2025-09-19","current":-1.365248,"twenty":-7.429707,"median":-1.872701,"eighty":-0.975257,"marketCap":216660791},{"date":"2025-09-26","current":-1.730404,"twenty":-7.422892,"median":-1.802474,"eighty":-0.975365,"marketCap":274609985},{"date":"2025-10-03","current":-1.656828,"twenty":-7.377457,"median":-1.775165,"eighty":-0.975365,"marketCap":262933655},{"date":"2025-10-10","current":-1.923883,"twenty":-7.30249,"median":-1.765048,"eighty":-0.975527,"marketCap":305314409},{"date":"2025-10-17","current":-1.910257,"twenty":-7.150283,"median":-1.79077,"eighty":-0.977747,"marketCap":303152125},{"date":"2025-10-24","current":-1.74403,"twenty":-7.070773,"median":-1.806706,"eighty":-0.98265,"marketCap":276772268},{"date":"2025-10-31","current":-1.839406,"twenty":-7.009436,"median":-1.817606,"eighty":-0.98374,"marketCap":291908252},{"date":"2025-11-07","current":-1.932058,"twenty":-6.429007,"median":-1.834596,"eighty":-0.986404,"marketCap":306611779},{"date":"2025-11-14","current":-1.76583,"twenty":-6.028046,"median":-1.829785,"eighty":-0.98707,"marketCap":280231922},{"date":"2025-11-21","current":-2.023973,"twenty":-5.954216,"median":-1.856881,"eighty":-0.988768,"marketCap":325843504},{"date":"2025-11-28","current":-2.086542,"twenty":-5.791787,"median":-1.873766,"eighty":-0.989487,"marketCap":335916623},{"date":"2025-12-05","current":-2.132789,"twenty":-5.650939,"median":-1.874832,"eighty":-0.990456,"marketCap":343361972},{"date":"2025-12-12","current":-2.27425,"twenty":-5.604368,"median":-1.895008,"eighty":-0.995653,"marketCap":366135981},{"date":"2025-12-19","current":-1.904276,"twenty":-5.571428,"median":-1.899357,"eighty":-1.000453,"marketCap":306573190},{"date":"2025-12-26","current":-2.445634,"twenty":-5.541896,"median":-1.907532,"eighty":-1.00316,"marketCap":393727568},{"date":"2026-01-02","current":-3.335677,"twenty":-5.503276,"median":-1.923883,"eighty":-1.005937,"marketCap":537017328},{"date":"2026-01-09","current":-2.998561,"twenty":-5.448754,"median":-1.93164,"eighty":-1.007666,"marketCap":482744300},{"date":"2026-01-16","current":-3.094373,"twenty":-5.404456,"median":-1.947802,"eighty":-1.008709,"marketCap":498169266},{"date":"2026-01-23","current":-3.729571,"twenty":-5.372651,"median":-1.953858,"eighty":-1.010478,"marketCap":600431076},{"date":"2026-01-30","current":-2.913395,"twenty":-5.344255,"median":-1.965361,"eighty":-1.010992,"marketCap":469033219},{"date":"2026-02-06","current":-2.579827,"twenty":-5.065967,"median":-1.978384,"eighty":-1.01346,"marketCap":415331486},{"date":"2026-02-13","current":-2.611764,"twenty":-5.054609,"median":-2.003915,"eighty":-1.013717,"marketCap":420473142},{"date":"2026-02-20","current":-2.87436,"twenty":-4.986457,"median":-2.025703,"eighty":-1.014247,"marketCap":462748974}],"updateTime":1771768154231},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KYTX\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2607083052","title":"Kyverna Therapeutics, Inc.盤中異動 股價大跌5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607083052","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607083052?lang=zh_tw&edition=fundamental","pubTime":"2026-01-28 22:50","pubTimestamp":1769611836,"startTime":"0","endTime":"0","summary":"北京时间2026年01月28日22时50分，Kyverna Therapeutics, Inc.股票出现异动，股价大幅下跌5.06%。Kyverna Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.78%。其相关个股中，Liminatus Pharma Inc C/Wts 30/04/2030 、Revolution Medicines Inc C/Wts 17/12/2026 、Nextcure, Inc.涨幅较大，Gri Bio, Inc.、60 Degrees Pharmaceuticals, Inc.、Calcimedica, Inc.较为活跃，换手率分别为1957.74%、116.29%、90.54%，振幅较大的相关个股有Jasper Therapeutics Inc C/Wts 24/09/2026 、Gri Bio, Inc.、Briacell Therapeutics Corp C/Wts ，振幅分别为85.71%、27.44%、25.75%。Kyverna Therapeutics, Inc.公司简介：Kyverna Therapeutics Inc是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260128225037a460de6c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260128225037a460de6c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","KYTX","BK4007","BK4139","BK4539"],"gpt_icon":0},{"id":"2602720983","title":"Kyverna Therapeutics, Inc.盤中異動 下午盤快速跳水5.06%報8.26美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2602720983","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602720983?lang=zh_tw&edition=fundamental","pubTime":"2026-01-09 04:02","pubTimestamp":1767902551,"startTime":"0","endTime":"0","summary":"北京时间2026年01月09日04时02分，Kyverna Therapeutics, Inc.股票出现波动，股价大幅跳水5.06%。截至发稿，该股报8.26美元/股，成交量57.6845万股，换手率0.97%，振幅6.76%。Kyverna Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为2.32%。其相关个股中，Enliven Therapeutics, Inc.、Century Therapeutics, Inc.、Moonlake Immunotherapeutics涨幅较大，Pmgc Holdings Inc.、Acrivon Therapeutics, Inc.、Gri Bio, Inc.较为活跃，换手率分别为527.89%、127.75%、81.83%，振幅较大的相关个股有Abpro Holdings Inc C/Wts 12/11/2029 、Enliven Therapeutics, Inc.、Briacell Therapeutics Corp C/Wts 26/02/2026，振幅分别为146.48%、59.43%、52.53%。Kyverna Therapeutics, Inc.公司简介：Kyverna Therapeutics Inc是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109040232953c3d0e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109040232953c3d0e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KYTX","LENZ","BK4007","BK4139","BK4539"],"gpt_icon":0},{"id":"2592917793","title":"BUZZ--美國股票走勢-Robinhood Markets、大麻股票、凱悦酒店","url":"https://stock-news.laohu8.com/highlight/detail?id=2592917793","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592917793?lang=zh_tw&edition=fundamental","pubTime":"2025-12-18 02:44","pubTimestamp":1765997053,"startTime":"0","endTime":"0","summary":"nL6N3XN0QE ** AAR Corp AIR.N:BUZZ - 杰富瑞给予 AAR Corp \"买入 \"评级。nL6N3XN0PR ** WesBanco Inc WSBC.O：** First Commonwealth Financial Corp FCF.N：** Financial Institutions Inc FISI.O：** Northwest Bancshares Inc NWBI.O:BUZZ - Piper Sandler 承担美国东北部五家银行的覆盖范围 nL4N3XN0V7 ** Waters Inc WAT.N：** Neogenomics Inc NEO.O：** Avantor Inc AVTR.N：** Danaher Corp DHR.N：BUZZ - 杰富瑞更新了2026年对生命科学公司的评级 nL4N3XN0WL ** McKesson Corp MCK.N：** Cencora Inc COR.N：** UnitedHealth Group Inc UNH.N：** CVS Health Corp CVS.N：BUZZ - J.P.Morgan 认为 2026 年美国医疗保健服务前景更加光明。nL4N3XN0WE ** Fortinet Inc FTNT.O:BUZZ - 在摩根大通将其评级下调至 \"减持 \"后下跌 nL6N3XN0W4 ** 通用磨坊GIS.N:BUZZ - 因需求稳定，季度业绩超出预期后上涨 nL6N3XN121","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nL4S3XN1MJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DHR","MCK","EQT","XENE","NUE","VOR","SCCO","UDMY","HUT","AIR","HL","HOOD","KYMR","AVTR","COUR","FTNT","UWMC","COR","COP","FISI","LNG","NEM","CVS","NEO","FCF","TWO","WMB","SPOT","CVX","INCY","NWBI","ABM","TE","WAT","GIS","PANW","FCX","KOD","IMNM","ALB","KYTX","UWMCW","XOM","H","FDX"],"gpt_icon":1},{"id":"2592795915","title":"BUZZ-Kyverna Therapeutics 因 1 億美元股票交易大幅折價而暴跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2592795915","media":"路透中文","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592795915?lang=zh_tw&edition=fundamental","pubTime":"2025-12-17 22:30","pubTimestamp":1765981801,"startTime":"0","endTime":"0","summary":"** Kyverna Therapeutics 的 KYTX.O 股价盘前下跌 29.1%，收于 7.27 美元，此前该公司的后续定价为 1 亿美元。** 公司在周一晚些时候公布  招股后，股价在周二下跌>5%。(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nL4T3XN185:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0211328371.USD","LU1064131342.USD","LU2023250330.USD","BK4516","BK4588","IE00B3S45H60.SGD","LU0106261372.USD","LU0320765489.SGD","LU2211815571.USD","LU0256863811.USD","LU1162221912.USD","IE00BKDWB100.SGD","IE0034235295.USD","LU0943347566.SGD","LU1244550577.SGD","BK4585","LU0868494617.USD","LU2505996681.GBP","LU1668664300.SGD","LU0267386448.USD","LU0345770993.USD","LU0211331839.USD","LU2552382058.USD","KYTX","LU0211327993.USD","IE0034235303.USD","LU1894683264.USD","LU2381873111.SGD","LU2746668974.SGD","IE00BDCRKT87.USD","BK4550","IE00BZ1G4Q59.USD","LU0234572021.USD","LU2430703095.HKD","IE00B775SV38.USD","LU0345770308.USD","LU1894683348.USD","LU1145028129.USD","IE00BJTD4N35.SGD","LU2505996509.AUD","LU0964807845.USD","LU0170899867.USD","LU1551013425.SGD","LU2552382215.SGD","LU0345769631.USD","IE00BHPRN162.USD","LU1988902786.USD","LU1084165304.USD","BK4139","LU2236285917.USD"],"gpt_icon":0},{"id":"2591624058","title":"BUZZ-Kyverna Therapeutics 因 1 億美元股票銷售計劃而下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2591624058","media":"路透中文","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591624058?lang=zh_tw&edition=fundamental","pubTime":"2025-12-16 05:38","pubTimestamp":1765834699,"startTime":"0","endTime":"0","summary":"** Kyverna Therapeutics公司KYTX.O计划增发股票的消息传出后，该公司股价在延时交易中下跌6.9%，至10.08美元。** 公司拥有约 4380 万股流通股，市值约 4.75 亿美元。(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nL4T3XL1G9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B1BXHZ80.USD","LU1720051017.SGD","LU0345769631.USD","LU2023250504.SGD","LU1116320901.HKD","LU0203347892.USD","LU2237443895.HKD","LU1894683264.USD","LU2456880835.USD","LU2237443622.USD","LU1496350502.SGD","LU0868494617.USD","LU0310799852.SGD","LU0640476718.USD","LU0496365809.HKD","IE00BFXG1179.USD","BK4534","LU2746668461.USD","LU0048584097.USD","LU0211326839.USD","IE00BKVL7J92.USD","LU1119994496.HKD","IE00BDRTCR15.USD","LU2552382215.SGD","LU1551013342.USD","LU2381873111.SGD","LU0942090050.USD","LU0265550946.USD","IE00BWXC8680.SGD","LU0820562030.AUD","LU0215105999.USD","LU0689472784.USD","LU1914381329.SGD","LU0787776722.HKD","LU0203345920.USD","LU2462157665.USD","IE00BJLML261.HKD","LU1917777945.USD","BK4207","LU2505996509.AUD","LU0683600562.USD","LU2213496289.HKD","IE00BKDWB100.SGD","LU0868494708.USD","LU1974910355.USD","LU1548497426.USD","LU0820561818.USD","LU2023250330.USD","KYTX","LU1366192091.USD"],"gpt_icon":0},{"id":"1124946336","title":"新聞稿：Kyverna Therapeutics宣佈擬進行普通股的公開發行","url":"https://stock-news.laohu8.com/highlight/detail?id=1124946336","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124946336?lang=zh_tw&edition=fundamental","pubTime":"2025-12-16 05:03","pubTimestamp":1765832595,"startTime":"0","endTime":"0","summary":"加利福尼亚州阿梅里维尔，2025年12月15日-- Kyverna Therapeutics, Inc.是一家专注于为自身免疫疾病患者开发细胞疗法的临床阶段生物制药公司，今天宣布已启动一项1亿美元的普通股承销公开发行。Kyverna打算给予承销商一个30天的选择权，以按照公开发行价格、扣除承销折扣和佣金的条件，额外购买最多1500万美元的普通股。所有将在拟议发行中出售的普通股均由Kyverna出售。J.P. Morgan、Leerink Partners、Morgan Stanley和Wells Fargo Securities作为该发行的联合簿记管理人。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0106261372.USD","BK4139","LU2133065610.SGD","LU1244550494.USD","LU2023251221.USD","LU0098860793.USD","LU0557290698.USD","LU1791710582.SGD","LU2111349929.HKD","LU2357305700.SGD","BK4581","LU1244550577.SGD","LU1989772840.SGD","LU2028103732.USD","LU0234570918.USD","LU2089284900.SGD","LU1363072403.SGD","LU1074936037.SGD","LU0158827781.USD","BK4504","LU0795875169.SGD","BK4585","LU0267386448.USD","BK4534","LU0225283273.USD","BK4516","LU0006306889.USD","LU2271345857.HKD","BK4127","LU0320765646.SGD","LU1791710400.SGD","BK4588","LU1989772923.USD","LU2089283258.USD","LU1720051108.HKD","IE00BZ1G4Q59.USD","LU0882574139.USD","LU1732799900.SGD","LU0528227936.USD","LU0971096721.USD","LU1244550221.USD","LU0795875086.SGD","LU1720051017.SGD","MS","LU1162221912.USD","LU1732800096.USD","LU0106831901.USD","LU1668664300.SGD","LU2347655156.SGD","LU0158827948.USD","LU0314104364.USD","LU0912757837.SGD","KYTX","LU1548497426.USD","IE00BKVL7J92.USD"],"gpt_icon":0},{"id":"2591649717","title":"BUZZ--美國股票走勢-通用美元公司、火箭實驗室、應用材料公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2591649717","media":"路透中文","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591649717?lang=zh_tw&edition=fundamental","pubTime":"2025-12-15 21:16","pubTimestamp":1765804570,"startTime":"0","endTime":"0","summary":".N** KLA Corp KLAC.O：** Lam Research Corp LRCX.O：** Nova Ltd NVMI.O:BUZZ - 杰富瑞认为人工智能将推动半导体需求从 2026 年开始激增；提升 KLA Corp 的评级。nL6N3XL0IZ ** Fastenal Co FAST.O:BUZZ - 因杰富瑞将其评级提升至 \"买入 \"而上涨，看好其增长。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nL4T3XL0VK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0274383776.USD","CDE","LU0265550946.USD","IE00BYXW3230.USD","LU1267930813.SGD","SCCO","IE00BZ1G4Q59.USD","LU1323610961.USD","LU2063271972.USD","FCX","DG","LU0868494708.USD","LU1267930573.SGD","KYTX","LU1992135399.USD","LU2746668461.USD","KLAC","LU1674673691.USD","BK4545","LU0505663152.USD","NCLH","LU1670628061.USD","LU2271345857.HKD","LU1235294995.USD","FAST","HL","LU0889565833.HKD","IE00BKVL7J92.USD","LU2756315664.SGD","LU2430703251.USD","AU","IE00BQXX3F31.USD","NEM","AMAT","BK4551","NOW","NVMI","BK4516","LU0323591593.USD","LU0316494557.USD","LU0011850046.USD","RKLB","SG9999002224.SGD","LU2244417387.USD","IE0034235295.USD","LRCX","FMC","LU0787776722.HKD"],"gpt_icon":1},{"id":"2591649712","title":"BUZZ--美國股票走勢-通用美元公司、火箭實驗室、應用材料公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2591649712","media":"路透中文","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591649712?lang=zh_tw&edition=fundamental","pubTime":"2025-12-15 21:16","pubTimestamp":1765804570,"startTime":"0","endTime":"0","summary":".N** KLA Corp KLAC.O：** Lam Research Corp LRCX.O：** Nova Ltd NVMI.O:BUZZ - 杰富瑞认为人工智能将推动半导体需求从 2026 年开始激增；提升 KLA Corp 的评级。nL6N3XL0IZ ** Fastenal Co FAST.O:BUZZ - 因杰富瑞将其评级提升至 \"买入 \"而上涨，看好其增长。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nL4S3XL0VK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2023250330.USD","CDE","LU1815336760.USD","LU1883866441.USD","SCCO","LU0208291251.USD","LU0820562030.AUD","IE00B7KXQ091.USD","IE00BLSP4239.USD","FCX","DG","KYTX","LU2242649171.HKD","LU1992135472.HKD","LU2462611646.USD","KLAC","LU1674673691.USD","LU0505663152.USD","LU2756315318.SGD","NCLH","LU0640476718.USD","LU0170899867.USD","LU0496367417.USD","FAST","HL","IE00BKVL7J92.USD","LU0964807845.USD","NEM","AU","SG9999002232.USD","AMAT","NVMI","NOW","SG9999001143.SGD","LU0820561818.USD","LU1551013425.SGD","IE00BHPRN162.USD","LU0048584097.USD","LU0868494617.USD","LU2211815571.USD","RKLB","LU2213496289.HKD","IE0034235295.USD","LRCX","LU0882574139.USD","FMC","LU2417539215.USD","LU0006306889.USD"],"gpt_icon":1},{"id":"2591643087","title":"BUZZ-細胞療法達到中期研究的主要目標後，Kyverna業績大增","url":"https://stock-news.laohu8.com/highlight/detail?id=2591643087","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591643087?lang=zh_tw&edition=fundamental","pubTime":"2025-12-15 19:53","pubTimestamp":1765799592,"startTime":"0","endTime":"0","summary":"12月15日 - ** 药物开发商Kyverna Therapeutics KYTX.O股价盘前上涨25.5%至11.02美元** 该公司 称 ，其用于治疗一种罕见运动障碍的实验性细胞疗法miv-cel在一项中期研究中达到了主要目标 ** Miv-cel 原名 KYV-101，目前正在僵人综合症患者中进行试验。僵人综合症是一种罕见的自身免疫性疾病，会使肌肉僵硬并引起疼痛性痉挛，通常难以正常行走或移动。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nL4T3XL0RG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX","BK4139"],"gpt_icon":0},{"id":"2591643650","title":"Kyverna的細胞療法達到了中期研究的主要目標","url":"https://stock-news.laohu8.com/highlight/detail?id=2591643650","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591643650?lang=zh_tw&edition=fundamental","pubTime":"2025-12-15 19:33","pubTimestamp":1765798385,"startTime":"0","endTime":"0","summary":"Kyverna的细胞疗法达到了中期研究的主要目标路透12月15日 - Kyverna Therapeutics KYTX.O周一表示，其治疗罕见运动障碍患者的实验性细胞疗法达到了一项中期研究的主要目标。(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nL4T3XL0QC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYTX"],"gpt_icon":0},{"id":"1196824119","title":"Kyverna Therapeutics公布Miv-Cel (Kyv-101)在僵人綜合徵註冊Kysa-8試驗中的積極關鍵數據","url":"https://stock-news.laohu8.com/highlight/detail?id=1196824119","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1196824119?lang=zh_tw&edition=fundamental","pubTime":"2025-12-15 19:30","pubTimestamp":1765798215,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics公布Miv-Cel (Kyv-101)在僵人综合征注册Kysa-8试验中的积极关键数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX","BK4139"],"gpt_icon":0},{"id":"1170285047","title":"Kyverna Therapeutics將發布Kyv-101在僵人綜合症註冊性第二階段Kysa-8試驗的頂線結果","url":"https://stock-news.laohu8.com/highlight/detail?id=1170285047","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170285047?lang=zh_tw&edition=fundamental","pubTime":"2025-12-15 03:31","pubTimestamp":1765740676,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics将发布Kyv-101在僵人综合症注册性第二阶段Kysa-8试验的顶线结果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX","BK4139"],"gpt_icon":0},{"id":"2581779056","title":"Caribou Biosciences報告了關於同種異體CAR T療法的臨牀數據，而Kyverna Therapeutics則推進了自身免疫項目Caribou Biosciences Reports Clinical Data on Allogeneic CAR T Therapies While Kyverna Therapeutics Advances Autoimmune Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2581779056","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581779056?lang=zh_tw&edition=fundamental","pubTime":"2025-11-05 16:03","pubTimestamp":1762329780,"startTime":"0","endTime":"0","summary":"Caribou presented findings from trials involving its allogeneic CAR T therapies, which use donor-derived cells rather than a patient’s own cells. These therapies were tested in two separate cancer indications, though specific details regarding efficacy or safety outcomes were not disclosed in the report.Caribou公布了其同种异体CAR T疗法的试验结果，该疗法使用捐赠者来源的细胞而非患者自身的细胞。Meanwhile, Kyverna announced plans to move forward with its CAR T program aimed at treating autoimmune conditions. This marks a shift from the traditional focus of CAR T therapy on oncology and represents an effort to expand the technology’s applications into other therapeutic areas. Both companies continue to explore innovative approaches within this rapidly evolving sector of biotechnology..同时，Kyverna 宣布计划推进其旨在治疗自身免疫性疾病的 CAR T 项目。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110516052697554e2c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110516052697554e2c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","CRBU","CAR","KYTX","BK4022","BK4539","BK4230","BK4007"],"gpt_icon":0},{"id":"1180745023","title":"Kyverna Therapeutics公司預計現金流可持續至2027年，支持其SPS的BLA申請及Mg三期臨牀試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=1180745023","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180745023?lang=zh_tw&edition=fundamental","pubTime":"2025-11-03 21:04","pubTimestamp":1762175058,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics公司预计现金流可持续至2027年，支持其SPS的BLA申请及Mg三期临床试验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYTX"],"gpt_icon":0},{"id":"1166583441","title":"Kyverna Therapeutics公布Kysa-6研究中Kyv-101在廣泛性重症肌無力治療中的積極一期2臨牀數據","url":"https://stock-news.laohu8.com/highlight/detail?id=1166583441","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166583441?lang=zh_tw&edition=fundamental","pubTime":"2025-10-29 18:31","pubTimestamp":1761733875,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics公布了Kysa-6研究中Kyv-101在广泛性重症肌无力治疗中的积极一期2临床数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX","BK4139"],"gpt_icon":0},{"id":"1104181247","title":"Kyverna Therapeutics在2025年Acr Convergence會議上展示的1期研究數據強調了Kyv-101在類風濕性關節炎中的潛力","url":"https://stock-news.laohu8.com/highlight/detail?id=1104181247","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104181247?lang=zh_tw&edition=fundamental","pubTime":"2025-10-25 23:00","pubTimestamp":1761404411,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics在2025年Acr Convergence会议上展示的1期研究数据强调了Kyv-101在类风湿性关节炎中的潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX","BK4139"],"gpt_icon":0},{"id":"2577555165","title":"Kyverna Therapeutics, Inc.盤中異動 股價大跌5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577555165","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577555165?lang=zh_tw&edition=fundamental","pubTime":"2025-10-24 03:43","pubTimestamp":1761248631,"startTime":"0","endTime":"0","summary":"北京时间2025年10月24日03时43分，Kyverna Therapeutics, Inc.股票出现异动，股价急速跳水5.02%。截至发稿，该股报6.34美元/股，成交量22.1233万股，换手率0.51%，振幅9.86%。Kyverna Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.21%。其相关个股中，Ventyx Biosciences, Inc.、Neumora Therapeutics, Inc.、Reviva Pharmaceuticals Holdings, Inc.涨幅较大，Nls Pharmaceutics Ltd.、Ventyx Biosciences, Inc.、Ibio, Inc.较为活跃，换手率分别为173.11%、157.57%、140.46%，振幅较大的相关个股有Nls Pharmaceutics Ltd C/Wts 02/02/2026、Neumora Therapeutics, Inc.、Ibio, Inc.，振幅分别为93.32%、46.18%、38.85%。Kyverna Therapeutics, Inc.公司简介：Kyverna Therapeutics Inc是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025102403435194da3ddd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025102403435194da3ddd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KYTX","BK4539","BK4139","BK4007","LENZ"],"gpt_icon":0},{"id":"1182652575","title":"Kyverna Therapeutics將在Ectrims會議上展示Kyv-101治療多發性硬化症的1期研究者發起試驗數據，凸顯該藥物潛力","url":"https://stock-news.laohu8.com/highlight/detail?id=1182652575","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182652575?lang=zh_tw&edition=fundamental","pubTime":"2025-09-24 21:06","pubTimestamp":1758719183,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics将在Ectrims会议上展示Kyv-101治疗多发性硬化症的1期研究者发起试验数据，凸显该药物潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX","BK4139"],"gpt_icon":0},{"id":"1105839120","title":"Kyverna Therapeutics在虛擬專家會議上重點介紹神經免疫學CAR-T業務及重症肌無力註冊性3期試驗設計","url":"https://stock-news.laohu8.com/highlight/detail?id=1105839120","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105839120?lang=zh_tw&edition=fundamental","pubTime":"2025-08-28 20:01","pubTimestamp":1756382501,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics在虚拟专家会议上重点介绍神经免疫学CAR-T业务及重症肌无力注册性3期试验设计","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYTX"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":19,"code":"91000000","status":"200"}]}}